Press release
Mucopolysaccharidosis Treatment Market Analysis, Recent Developments Trends, CAGR Analysis, Top Players And Outlook
Mucopolysaccharidosis Treatment Market Analysis
As per the report, the mucopolysaccharidosis treatment market size has grown strongly in recent years. It will grow from $2.2 billion in 2023 to $2.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The mucopolysaccharidosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.19 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%.
Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=11942&type=smp
Rising Prevalence Of Mucopolysaccharidosis Sparks Growth In The Mucopolysaccharidosis Treatment Market
The increasing prevalence of various forms of mucopolysaccharidosis is expected to propel the growth of the mucopolysaccharidosis treatment market going forward. Mucopolysaccharide is a form of complex carbohydrate that accumulates in bodily tissues because the individual affected lacks the particular enzyme required to digest it. Mucopolysaccharidosis (MPS) therapy can help prevent disease development by lowering glycosaminoglycan (GAG) formation in the body, controlling symptoms, and preventing complications through various therapeutic approaches. For instance, in February 2021, according to a report shared by National Library of Medicine, a US-based medical library, there were 3.62 MPS I and MPS VI births for every 100,000 live births. MPS III represented 11% of all cases, with a calculated rate of 1.8 per 100,000 live births. Therefore, the increasing prevalence of various forms of mucopolysaccharidosis will drive the mucopolysaccharidosis treatment market.
Jcr Pharmaceuticals Unveils Mucopolysaccharidosis Therapy With Blood-Brain Barrier Penetration
Product innovation is a key trend gaining popularity in the mucopolysaccharidosis treatment market. Major companies operating in the mucopolysaccharidosis treatment market are focused on new product innovations to sustain their position in the market. For instance, in March 2021, JCR Pharmaceuticals, a Japan-based pharmaceuticals company, announced the approval of IZCARGO (Pabinafusp Alfa) for the treatment of mucopolysaccharidosis II (MPS II, or Hunter syndrome) in Japan. It is the first approved enzyme replacement therapy for MPS II to penetrate the blood-brain barrier via intravenous administration, validating JCR's J-Brain Cargo Technology. The product is a recombinant iduronate-2-sulfatase enzyme replacement therapy (ERT) that uses J-Brain Cargo, a proprietary technology that delivers therapeutics across the blood-brain barrier (BBB). It is the first-ever approved ERT that crosses the BBB via intravenous administration, which could be life-changing for people with lysosomal storage disorders (LSDs) like MPS II.
The mucopolysaccharidosis treatment market covered in this report is segmented -
1) By Treatment: Enzyme Replacement Therapy, Stem Cell Therapy
2) By Disease: Mucopolysaccharidosis- I, Mucopolysaccharidosis- II, Mucopolysaccharidosis-IV, Mucopolysaccharidosis-VI, Other Diseases
3) By Route of Administration: Intravenous, Intracerebroventricular
4) By End-User: Hospitals, Specialty Clinics, Other End-Users
Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=11942&type=discount
Major companies operating in the mucopolysaccharidosis treatment market report are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., BioMarin Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Sarepta Therapeutics Inc., Esteve SA, JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Eidos Therapeutics Inc., Neurogene Inc., Immusoft Corporation, Bioasis Technologies Inc., Paradigm Biopharmaceuticals Ltd., Rimedion Inc., Eloxx Pharmaceuticals Inc., iBio Inc., Abeona Therapeutics Inc.
Contents of the report:
1. Executive Summary
2. Mucopolysaccharidosis Treatment Market Report Structure
3. Mucopolysaccharidosis Treatment Market Trends And Strategies
4. Mucopolysaccharidosis Treatment Market - Macro Economic Scenario
5. Mucopolysaccharidosis Treatment Market Size And Growth
…..
27. Mucopolysaccharidosis Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/mucopolysaccharidosis-treatment-global-market-report
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mucopolysaccharidosis Treatment Market Analysis, Recent Developments Trends, CAGR Analysis, Top Players And Outlook here
News-ID: 3591833 • Views: …
More Releases from The Business research company
Aerospace Forging Market Anticipated To Witness Robust Growth, Surpassing $49.66 …
The Aerospace Forging Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Aerospace Forging Market Size and Its Estimated Growth Rate?
The Aerospace Forging Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.…
Fuel Efficiency Advancements Fueling Growth In The Advanced Lead-Acid Batteries …
The Advanced Lead Acid Battery Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Advanced Lead Acid Battery Market Size and Its Estimated Growth Rate?
The Advanced Lead Acid Battery Market Report by The Business Research Company delivers a detailed market assessment, covering…
Acrylic Rubber Market Report 2025-2034: Industry Overview, Trends, And Forecast …
The Acrylic Rubber Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Acrylic Rubber Market Size and Its Estimated Growth Rate?
The Acrylic Rubber Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.…
5G NTN Market Anticipated To Witness Robust Growth, Surpassing $17.01 Billion By …
The 5G NTN Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current 5G NTN Market Size and Its Estimated Growth Rate?
The 5G NTN Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.…
More Releases for Mucopolysaccharidosis
Mucopolysaccharidosis Therapeutics Market May Set Huge Growth by 2027 | Denali T …
The Mucopolysaccharidosis Therapeutics Market Report addresses a 360-degree outline of significant market players that will affect the general development of industry. It offers itemized and brief examination of different key angles like drivers, limitations and worldwide freedoms. This market report dissects gigantic information identified with market size, share, creating patterns and cutthroat situations regarding all areas like North America, Europe, China and Japan and so forth the report offers request…
Mucopolysaccharidosis I Market Report- Size by Trends, Key Players, Driver, Segm …
The Mucopolysaccharidosis I Market research report provides wide-range coverage of the Mucopolysaccharidosis I Market in the forecast period 2021-2026. It provides historical, current, and future trends of the market that help develop robust market strategy addition. In addition, Mucopolysaccharidosis I Market offers value chain analysis, key drivers and challenges, and includes upcoming opportunities in the Mucopolysaccharidosis I Market that will enable business success.
Get FREE PDF Sample of the Report @…
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipelin …
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems.
Download the sample report @ https://www.pharmaproff.com/request-sample/1146
In later stages of this disorder, people…
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics - Pipeline Analys …
Mucopolysaccharidosis type I (MPS I) is a condition that affects many parts of the body. Earlier, MPS I disorder was divided into three separate syndromes; Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H/S), and Scheie syndrome (MPS I-S), listed from most to least severe.
Download the sample report at: https://www.pharmaproff.com/request-sample/1144
Later on, these were clubbed as one disease, due to overlap between each of these three syndromes. Children with MPS I…
Gene Therapy for Mucopolysaccharidosis-A Pipeline Analysis Report
This pipeline analysis report provides detailed insights into the clinical trials landscape of the Gene Therapy For Mucopolysaccharidosis including molecules at pre-clinical and various other development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations including route of administration
Download PDF Sample of Gene Therapy for Mucopolysaccharidosis Market Report@ http://orbisresearch.com/contacts/request-sample/2099662
The global Gene Therapy for Mucopolysaccharidosis report is a gem in terms…
Government Support will boost Mucopolysaccharidosis Treatment Market size During …
The mucopolysaccharidosis (MPS) is an inherited lysosomal storage disorders. It refers to the deficiency of the enzyme that is involved in the degradation of acid mucopolysaccharides. The enzyme is known as glycosaminoglycans (GAGs). Mucopolysaccharidosis affects many parts of the body and is caused due to the mutation of the IDUA gene. Due to the mutation of the IDUA gene, larger sugar molecules known as glycosaminoglycans, accumulate in the cells known…
